John George McHutchison

Journal article Gastroenterology · April 2010 BACKGROUND & AIMS: Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activates peroxisome proliferator-activated receptor gamma (PPARgamma) and inhibits stellate cell activation. We evaluated its antifibrotic effect in patients wi ... Full text Link to item Cite

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Journal article N Engl J Med · August 6, 2009 BACKGROUND: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. METHODS: At 118 sit ... Full text Link to item Cite

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Journal article N Engl J Med · April 30, 2009 BACKGROUND: Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV R ... Full text Link to item Cite

Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C.

Journal article Aliment Pharmacol Ther · March 1, 2008 BACKGROUND: Treatment options are limited for patients with hepatitis C virus who do not experience sustained viral eradication with pegylated interferon and ribavirin therapy. AIM: To compare, in an open-label, randomized study, long-term continuous inter ... Full text Link to item Cite

Making it happen: managed care considerations in vanquishing hepatitis C.

Journal article Am J Manag Care · December 2007 Chronic hepatitis C virus (HCV) infection is an area of medical and economic concern. Studies show a substantial and increasing use of healthcare resources by patients with this disease. However, analysis of available data regarding virologic efficacy, imp ... Link to item Cite

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

Journal article N Engl J Med · November 29, 2007 BACKGROUND: Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocyto ... Full text Link to item Cite

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.

Journal article Hepatology · November 2007 UNLABELLED: CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-p ... Full text Link to item Cite

Definition and management of anemia in patients infected with hepatitis C virus.

Journal article Liver Int · May 2006 Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin. Although this regi ... Full text Link to item Cite

The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.

Journal article J Hepatol · February 2006 Full text Link to item Cite

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.

Journal article J Hepatol · January 2006 BACKGROUND/AIMS: ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell cultu ... Full text Link to item Cite

Chronic hepatitis C: an age wave of disease burden.

Journal article Am J Manag Care · October 2005 There are at least 2.7 million individuals in the United States, most of them in their 40s and 50s, who are chronically infected with hepatitis C virus (HCV). As these infected individuals get older, about 20% will develop cirrhosis, and a significant frac ... Link to item Cite

A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.

Journal article Antivir Ther · 2005 Inhibition of inosine monophosphate dehydrogenase (IMPDH) is one of several proposed mechanisms of action for ribavirin (RBV), a critical component of the current treatment for chronic hepatitis C (CHC). This study was a double-blind, placebo-controlled do ... Link to item Cite

Future trends in managing hepatitis C.

Journal article Gastroenterol Clin North Am · March 2004 Despite recent improvements in the treatment of patients who have chronic hepatitis C, a large proportion of patients do not achieve viral clearance. Treatment regimens are also costly, associated with significant morbidity, require substantial patient com ... Full text Link to item Cite

Future therapy of hepatitis C.

Journal article Hepatology · November 2002 Currently available therapies for the treatment of chronic hepatitis C are effective in half of patients, but are expensive, often poorly tolerated, and unsuitable for certain patient populations. The ideal therapy would be highly effective, orally bioavai ... Full text Link to item Cite